Abstract
Introduction: Although safety data demonstrated the efficacy and effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination for all individuals over 6 months of age, including pregnant and breastfeeding individuals, optimal treatment courses for symptomatic pregnant and lactating individuals infected with SARS-CoV-2 remain to be defined. Case Description: A coronavirus disease 2019 (COVID-19)-vaccinated breastfeeding woman received anti-SARS-CoV-2 monoclonal antibody treatment casirivimab-imdevimab 5 days after diagnosis of a symptomatic breakthrough SARS-CoV-2 infection. Results and Conclusions: The patient did not present with obvious defects in innate or adaptive cellular subsets, but compared with controls had minimal maternal antibody response to recommended pregnancy vaccinations including SARS-CoV-2 and tetanus, diphtheria, pertussis (TDaP). The outcome of the monoclonal antibody infusion treatment was favorable as it transiently increased SARS-CoV-2 antibody titers in plasma and human milk compartments.
| Original language | English |
|---|---|
| Pages (from-to) | 626-630 |
| Number of pages | 5 |
| Journal | Breastfeeding Medicine |
| Volume | 18 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 1 2023 |
Bibliographical note
Publisher Copyright:© Copyright 2023, Mary Ann Liebert, Inc., publishers 2023.
Funding
This research was supported by grants from the National Institutes of Health R01AI145910 (I.M.) and R01AI142841 (I.M.). The funding source had no involvement in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
| Funders | Funder number |
|---|---|
| National Institutes of Health (NIH) | R01AI142841, R01AI145910 |
Keywords
- SARS-CoV-2 infection
- immune response
- lactation
- monoclonal antibody therapy
ASJC Scopus subject areas
- Pediatrics
- Health Policy
- Obstetrics and Gynecology
- Maternity and Midwifery
